Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
In order to explore a new treatment strategy for patients with failed NSCLC
platinum-containing double-drug therapy, this study was to investigate the clinical efficacy
of apatinib in combination with docetaxel for patients with advanced NSCLC after failure of
platinum-based regime